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Resistance to cephalosporins in Haemophilus influen-
zae is usually caused by characteristic alterations in 
penicillin-binding protein 3 (PBP3), encoded by the 
ftsI gene. Resistance to extended-spectrum cephalo-
sporins is associated with high-level PBP3-mediated 
resistance (high-rPBP3), defined by the second stage 
S385T substitution in addition to a first stage sub-
stitution (R517H or N526K). The third stage L389F 
substitution is present in some high-rPBP3 strains. 
High-rPBP3 H. influenzae are considered rare outside 
Japan and Korea. In this study, 30 high-rPBP3 iso-
lates from Norway, collected between 2006 and 2013, 
were examined by serotyping, multilocus sequence 
typing (MLST), ftsI sequencing, detection of beta-
lactamase genes and minimum inhibitory concen-
tration (MIC) determination. MICs were interpreted 
according to clinical breakpoints from the European 
Committee on Antimicrobial Susceptibility Testing 
(EUCAST). Respiratory isolates predominated (propor-
tion: 24/30). The 30 isolates included one serotype f 
isolate, while the remaining 29 lacked polysaccha-
ride capsule genes. Resistance to extended-spectrum 
cephalosporins (cefixime, 29 isolates/30 isolates; 
cefepime, 28/30; cefotaxime, 26 /30; ceftaroline, 
26/30; ceftriaxone, 14/30), beta-lactamase produc-
tion (11/30) and co-resistance to non-beta-lactams 
(trimethoprim-sulfamethoxazole, 13/30; tetracycline, 
4/30; chloramphenicol, 4/30; ciprofloxacin, 3/30) was 
frequent. The N526K substitution in PBP3 was pre-
sent in 23 of 30 isolates; these included a blood iso-
late which represents the first invasive S385T + N526K 
isolate reported from Europe. The L389F substitution, 
present in 16 of 30 isolates, coincided with higher 
beta-lactam MICs. Non-susceptibility to meropenem 
was frequent in S385T + L389F + N526K isolates (8/12). 
All 11 beta-lactamase positive isolates were TEM-1. 
Five clonal groups of two to 10 isolates with identical 
MLST-ftsI allelic profiles were observed, including the 
first reported high-rPBP3 clone with TEM-1 beta-lacta-
mase and co-resistance to ciprofloxacin, tetracycline, 
chloramphenicol and trimethoprim-sulfamethoxazole. 
Prior to this study, no multidrug resistant high-rPBP3 
H. influenzae had been reported in Norway. Intensified 
surveillance of antimicrobial resistance is needed to 
guide empiric therapy. 
Introduction
Haemophilus influenzae colonises the respiratory tract 
in humans and infection causes a wide range of con-
ditions, including acute otitis media, arthritis, con-
junctivitis, epiglottitis, meningitis, respiratory tract 
infections, septicaemia and sinusitis [1]. Encapsulated 
isolates of serotype b (Hib) have the highest potential 
for invasive disease but the introduction of Hib vac-
cines has dramatically reduced the burden of disease. 
Thus, the vast majority of infections, both invasive and 
non-invasive, are currently caused by nontypeable (i.e. 
lacking polysaccharide capsule) H. influenzae (NTHi) 
and non-b serotypes, mainly serotype f (Hif) [1-3].
Due to the global emergence of beta-lactamase (TEM-1 
and ROB-1) producing strains in the 1970s, empiric 
therapy for severe disease caused by H. influenzae 
was altered from ampicillin to cephalosporins [4]. 
Development of resistance to extended-spectrum 
cephalosporins has forced a second shift in empiric 
treatment to carbapenems in some geographical 
areas [4]. The European Committee on Antimicrobial 
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Susceptibility Testing (EUCAST) categorises resist-
ance to extended-spectrum cephalosporins in H. influ-
enzae as an exceptional phenotype [5]. Considering 
such isolates ‘very rare or not yet reported’, EUCAST 
recommend that they are sent to a reference labora-
tory [6]. Notably, minimum inhibitory concentration 
(MIC) breakpoints for cephalosporins and H. influenzae 
from EUCAST are considerably lower than those from 
Clinical and Laboratory Standards Institute (CLSI): for 
instance, the susceptible minimum inhibitory concen-
tration (MIC) breakpoint for cefotaxime from EUCAST 
is ≤ 0.12 mg/L while the corresponding CLSI breakpoint 
is ≤ 2 μg/mL [7].
Resistance to cephalosporins is due to alterations in 
the transpeptidase domain of penicillin-binding pro-
tein 3 (PBP3), encoded by the ftsI gene, with pheno-
typic resistance profiles depending on amino acid 
substitution patterns. Several genotypic classification 
systems for PBP3-mediated resistance (rPBP3) have 
been suggested and the terminology is still develop-
ing [4,8-13]. Acquirement of one of the substitutions 
R517H or N526K represents the first stage of resistance 
development. The second stage substitution S385T is 
associated with increased resistance to cefotaxime 
and separates high-level resistant (high-rPBP3) iso-
lates from those with low-level resistance (low-rPBP3) 
[4,12,13]. High-rPBP3 strains may be divided into group 
III (S385T + N526K) and group III-like (S385T + R517H) 
[9-11]. The additional L389F substitution is associated 
with further increased resistance levels in high-rPBP3 
strains and may be considered the third stage in devel-
opment of PBP3-mediated resistance [13].
High-rPBP3 isolates became frequent in Japan in the 
late 1990s [14] and in Korea during the 2000s [15]. A 
similar development in other geographical areas would 
compromise current empiric antimicrobial therapy 
in severe infections, which is largely based on third-
generation cephalosporins. However, low-rPBP3 H. 
influenzae, lacking the S385T substitution and mainly 
susceptible to cefotaxime and ceftriaxone, still predom-
inate in south-west and northern Europe [2,8,11,16]. In 
previous systematic surveys outside Asia where deter-
mination of PBP3 amino acid substitution patterns has 
been performed [2,3,8,11,16-19], very few group III iso-
lates have been reported [1]; these include one inva-
sive isolate from Canada [19], one otitis media isolate 
from France [16] and one upper respiratory tract isolate 
from Norway [8]. Group III-like isolates have been more 
frequently reported in Europe [1,3,8,11,16,18].
Since 2007, the Norwegian Working Group on 
Antibiotics (NWGA) has recommended that cefotaxime 
resistant H. influenzae isolates are sent to the reference 
laboratory for ftsI sequencing and susceptibility test-
ing with broth microdilution. In Norway, this is carried 
out at Vestfold Hospital Trust, in collaboration with the 
Haemophilus Reference Laboratory at the Norwegian 
Institute of Public Health and the Norwegian National 
Advisory Unit on Detection of Antimicrobial Resistance 
at the University Hospital of North Norway. We present 
here susceptibility profiles, resistance genotypes and 
molecular strain characteristics of 30 high-rPBP3 iso-
lates from Norway, defined by the S385T substitution, 
collected between May 2006 and July 2013.
Methods
Isolates
A total of 30 clinical high-rPBP3 (S385T positive) H. 
influenzae isolates from Norway, isolated at 10 differ-
ent routine laboratories between May 2006 and July 
2013, were included in the study. Of the 30 high-rPBP3 
isolates, 27 (from 7 laboratories) with the S385T sub-
stitution were identified by partial ftsI sequencing of 
39 routine isolates (from 10 laboratories) with cefo-
taxime MIC > 0.12 mg/L (gradient test); the remaining 
12 isolates were categorised as group II low-rPBP3 
(N526K positive, S385T negative) and had cefotaxime 
MIC = 0.25 mg/L (n = 10) or 0.5 mg/L (n = 2) by gradi-
ent test. We also included three isolates (isolates 4–6) 
from three additional laboratories, collected in 2007 
and identified as high-rPBP3 through a previous sur-
veillance study [8]. The 10 laboratories contributing the 
30 isolates were located in mid Norway (Nord-Trøndelag 
county), the Oslo region (Akershus, Buskerud, Oslo and 
Vestfold counties), Western Norway (Sogn og Fjordane, 
Hordaland and Rogaland counties) and Southern 
Norway (Agder county).
Pure cultures were kept frozen at -70 °C in Microbank 
vials (Pro-Laboratory Diagnostics, Ontario, Canada) 
pending further characterisation.
Demographic and clinical data
Information about sample types, demographic data 
and brief clinical information (provided by the clinician 
at the time of sampling) were acquired from the pri-
mary laboratories. Three recently hospitalised patients 
with X-ray confirmed pneumonia most likely caused by 
study isolates were selected as case reports. For these 
patients, relevant supplementary information about 
diagnosis, antimicrobial therapy and clinical outcome 
was extracted from the patient files.
Species identification and molecular 
characterisation
Species identification was carried out by API NH (bio-
Mérieux, Marcy-l’Etoile, France), matrix-assisted laser 
desorption/ionisation-time of flight (MALDI-TOF) mass 
spectrometry with MALDI Biotyper (Bruker Daltonics 
GmbH, Bremen, Germany), and conventional methods, 
including absence of beta-haemolysis on blood agar. 
Amplification of the fucK gene when performing multi-
locus sequence typing (MLST) (see below) was used as 
an additional criterion to separate H. influenzae from H. 
haemolyticus; all included isolates were fucK positive.
Biotypes [20] were determined using indole, urease 
and ornithine decarboxylase (ODC) reactions produced 
by API NH (bioMérieux).
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Capsular serotyping was performed at the Norwegian 
Institute of Public Health according to previously 
described methodology [21] with modifications (under-
scored) to the e1 (TTTGGTAACGAATGTAGTGGTAG) and 
e2 (ATAGCTTTACTGTATAAGTCTTAG) primers (5´ to 3´).
MLST with sequencing of the seven housekeeping 
genes adk, atpG, frdB, fucK, mdh, pgi and recA was 
carried out at the Norwegian Institute of Public Health 
according to standard procedures [22]. Sequences were 
registered at http://haemophilus.mlst.net. Sequence 
types (ST) were assigned according to allelic profiles. 
STs were divided into clonal complexes (CC) (named 
according to founder) using eBURST Version 3 (http://
haemophilus.mlst.net/eburst).
Pulsed-field gel electrophoresis (PFGE) of selected iso-
lates was carried out at Unilabs Telelab (Skien, Norway) 
as previously described [17] and clonal relatedness was 
interpreted according to the Tenover criteria [23].
Beta-lactamase detection
All isolates were screened for beta-lactamase produc-
tion and the presence of beta-lactamase genes (TEM-1 
and ROB-1) as previously described using acidimetric 
agar [24] and polymerase chain reaction (PCR) [17].
Minimum inhibitory concentration 
determination
MICs to ampicillin, amoxicillin (ampicillin-sulbactam 
2:1 ratio and amoxicillin-clavulanic acid 2:1 ratio for 
beta-lactamase positive isolates), cefuroxime, cefix-
ime, cefotaxime, ceftriaxone, cefepime, imipenem, 
meropenem, ciprofloxacin, levofloxacin, chloramphen-
icol, tetracycline and trimethoprim-sulfamethoxazole 
were determined by broth microdilution according to 
CLSI methodology [25] at Vestfold Hospital Trust, using 
standard Sensititre plates (HPB1, STP6 and GNX3F; 
TREK Diagnostic Systems, Thermo Fisher Scientific, 
West Sussex, UK). Ceftaroline, azithromycin, clarithro-
mycin, erythromycin, roxithromycin, telithromycin, 
doxycycline, minocycline and rifampicin MICs were 
determined at the EUCAST Development Laboratory, 
using custom Sensititre plates (SEFE3, TREK) with in-
house prepared EUCAST MH-F broth (cation-adjusted 
Mueller-Hinton broth (BBL, BD Diagnostic Systems, 
Franklin Lakes, NJ) with 5% lysed horse blood and 
20 mg/L beta-NAD) and 16 to 20 hours incubation in 
sealed panels in ambient air. H. influenzae ATCC 49247, 
H. influenzae ATCC 49766 and H. influenzae ATCC 35056 
(ampicillin-sulbactam and amoxicillin-clavulanic acid 
only) were incorporated for quality control purposes, 
with all MICs within accepted ranges. MICs were inter-
preted according to EUCAST clinical breakpoints [6]. 
MICs of all study isolates are included in the EUCAST 
MIC database (www.eucast.org/MIC_distributions).
ftsI/penicillin-binding protein 3 typing
PCR of the ftsI gene (transpeptidase domain) was per-
formed as described previously [17]. Sequencing was 
performed at GATC Biotech AG (Konstanz, Germany). 
Sequences were analysed with the Lasergene software 
(DNASTAR, Madison, WI, US). An unweighted pair group 
method with arithmetic mean (UPGMA) phylogram 
(nucleotides 1010–1719) was created using ClustalW2 
(www.ebi.ac.uk) and TreeDyn (www.phylogeny.fr). 
H. influenzae Rd KW20 (GenBank accession number: 
cU32793) was used as reference and H. parainfluenzae 
(European Molecular Biology Laboratory (EMBL) acces-
sion number: AB267856) as outgroup. The 710 bp frag-
ments (hereafter denoted ftsI alleles) were assigned 
numbers (1–10) according to frequency of occurrence 
and used together with MLST allelic profiles for assign-
ment to clonal groups (CG) (see below).
Deduced PBP3 amino acid sequences (338–573) were 
compared with H. influenzae Rd KW20 and sequence 
patterns (denoted PBP3 types) were assigned num-
bers (1–7) according to frequency of occurrence. The 
substitutions S385T, R517H and N526K were used for 
categorisation into PBP3 group III and group III-like 
[9-11]. For isolates with the third stage substitution 
L389F, the suffix ‘ + ’ was added. The following group 
designations were thus used: group III (S385T, N526K); 
group III+ (S385T, L389F, N526K); group III-like (S385T, 
R517H); group III-like+ (S385T, L389F, R517H). The 
groups respectively correspond to PBP3 classes II, III, 
V and VI, proposed by Osaki et al. [13].
Clonal groups
According to a previously described approach to molec-
ular typing of H. influenzae [4], CGs were defined as 
isolates with identical MLST-ftsI allelic profiles and 
numbered chronologically [1-5].
GyrA and ParC amino acid substitutions
For isolates with ciprofloxacin MIC > 0.06 mg/L and/or 
levofloxacin MIC > 0.03 mg/L, the quinolone-resistance 
determining regions (QRDR) of gyrA and parC were 
characterised by PCR methodology adapted from a 
previous report [26]. DNA sequencing of amplified 
products was carried out at GATC Biotech. Sequences 
were analysed with Lasergene. Deduced amino acid 
sequences of GyrA (64–177) and ParC (66–236) were 
compared with H. influenzae Rd KW20 (GenBank acces-
sion number: U32793).
Nucleotide sequences
The ftsI (HG983286–HG983315), gyrA (HG983316–
HG983320) and parC (HG983321–HG983325) 
sequences from this study are available at the European 
Nucleotide Archive (www.ebi.ac.uk).
Ethics
The use of clinical data in this study is approved by the 
Regional Committees for Medical and Health Research 
Ethics in Norway (reference number 2014/411).
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Table 1
Characterisation of Haemophilus influenzae with high-level penicillin-binding protein 3-mediated beta-lactam resistance 
(high-rPBP3), Norway, 2006–2013 (n=30)
Isolatea Year/regionb
Categoryc/
age groupd Site
e Clinical dataf Biotypeg
MLST
ftsIh Clonal groupi
PBP3
Co-resistancel
ST CC Typej Groupk
1 2006 O Hosp 1 Nose ALL/AOM III 155 155 3 1 4 III-like –
2 2007 O GP 1 Nose URTI IV 1197 395 1 2 1 III β
3 2007 O GP 5 Npx No data III 159 503 6 Single 5 III+ Ts
4 2007 O OC 3 Nose No data IV 1197 395 1 2 1 III –
5 2007 O OC 1 Npx No data III 155 155 3 1 4 III-like –
6 2007 M Hosp 7 LRT No data III 155 155 3 1 4 III-like –
7 2008 O GP 3 Npx No data III 1197 395 1 2 1 III –
8 2008 O Hosp 1 Nose URTI IV 1197 395 1 2 1 III –
9 2008 O GP 1 Npx No data IV 1197 395 1 2 1 III –
10 2008 O GP 1 Nose No data IV 1197 395 1 2 1 III –
11 2009 O GP 5 Npx Sinusitis I 408 3 7 Single 6 III+ –
12 2009 W OC 1 Ear AOM IV 1197 395 1 2 1 III –
13 2009 W GP 6 Nose Sinusitis III 1197 395 1 2 1 III –
14 2009 W GP 1 Ear AOM III 1197 395 1 2 1 III –
15 2010 W GP 1 Npx AOM III 1197 395 1 2 1 III –
16 2011 O GP 1 Eye Conjunctivitis II 422 422 4 3 3 III-like+ β,q,Ts
17 2011 O GP 4 Nose Sinusitis II 142 142 8 Single 3 III-like+ –
18 2012 S Hosp 8 Blood MM/pneumonia I 1287 None 9 Single 7 III –
19 2012 W OC 8 BAL COPD/DC II 160 160 2 Single 2 III+ Ts
20 2012 W OC 1 Sputum CF III 148 245 10 Single 2 III+ –
21 2012 O GP 1 Ear AOM I 124 124 2 Single 2 III+ Ts
22 2013 W GP 8 Sputum Pneumonia IV 1282 503 4 Single 3 III-like+ β,C,T,Ts
23 2013 Om Hosp 7 Nose Pneumonia II 422 422 4 3 3 III-like+ β,q,Ts
24 2013 W Hosp 8 Eye Dacryocystitis III 159 503 5 4 2 III+ β,Q,C,T,Ts
25 2013 W OC 1 Npx PCD III 159 503 5 4 2 III+ β,Q,C,T,Ts
26 2013 W OC 4 Sputum CF/pharyngitis III 159 503 5 4 2 III+ β,Q,C,T,Ts
27 2013 W Hosp 8 Sputum CVD/pneumonia IV 836 245 2 5 2 III+ β,Ts
28 2013 W Hosp 8 Sputum DC/pneumonia III 836 245 2 5 2 III+ β,Ts
29 2013 W Hosp 7 Sputum COPD/pneumonia IV 836 245 2 5 2 III+ β,Ts
30 2013 W Hosp 8 Npx Possible pneumonia III 836 245 2 5 2 III+ β,Ts
 CC: clonal complex; MLST: multilocus sequence typing; PBP3: penicillin-binding protein 3; ST: sequence type.
a  All isolates lacked polysaccharide capsule genes except for isolate 21 (serotype f).
b  M: mid Norway (Nord-Trøndelag); O: Oslo region (Oslo, Akershus, Buskerud, Vestfold); S: Southern Norway (Agder); W: Western Norway  
(Sogn og Fjordane, Hordaland, Rogaland).
c  GP: general practice; Hosp: hospitalised; OC: outpatient clinic.
d  1: 0–9 years; 2: 10–19 years; 3: 20–29 years; 4: 30–39 years; 5: 40–49 years; 6: 50–59 years; 7: 60–69 years; 8: ≥70 years.
e  BAL: bronchioalveolar lavage; LRT: lower respiratory tract; Npx: nasopharynx.
f  ALL: acute lymphoblastic leukemia; AOM: acute otitis media; CF: cystic fibrosis; COPD: chronic obstructive pulmonary disease; CVD: 
cardiovascular disease; DC: disseminated cancer; MM: multimorbidity (hypogammaglobulinemia, chronic lymphocytic leukaemia, 
myasthenia gravis, COPD); PCD: primary ciliary dyskinesia; URTI: upper respiratory tract infection.
g  According to reactions (positive (+) or negative (-)) to indole, urease and ornithine decarboxylase (ODC) respectively. I: +/+/+; II: +/+/-; III: 
-/+/-; IV: -/+/+ [18].
h  ftsI alleles (Figure 1).
i  Isolates with identical MLST-ftsI allelic profiles (Figure 1). Isolates qualified as ‘single’ are those among the 30 analysed with a unique 
MLST-ftsI allele combination. 
j  PBP3 type according to amino acid sequences (substitutions underscored) in positions 350, 357, 377, 385, 389, 502, 517, 526, 532, 547, 557, 
562 and 569. 1: NNMTLTRKTIYVS; 2: NNITFARKTIYLS; 3: NNITFAHNSIHVS; 4: NNITLAHNSIYVN; 5: NNITFTRKTVYVN; 6: NNITFTRKTVYLN;  
7: DSMTLTRKTIYVS.
k  Group III: S385T and N526K; group III+: S385T, L389F and N526K; group III-like: S385T and R517H; group III-like+: S385T, L389F and R517H.
l  β: TEM-1 beta-lactamase; Q: quinolones; q: quinolones (low level resistant); C: chloramphenicol; T: tetracyclines; Ts: trimethoprim-
sulfamethoxazole; –: none.
m Recently travelled to Thailand.
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Results
Patient data
The median age of the 30 patients from whom the 
respective isolates were derived, was 29 years (range: 
0–91). In the age group zero to nine years, most 
patients (proportion: 10/13) were below five years-old. 
The male/female ratio was 13/17. All but two patients 
lived in the Oslo region (14/30) or in Western Norway 
(14/30). Except for the patient with isolate 23, recently 
returning from Thailand, there was no known recent (< 3 
months) travel history abroad (Table 1).
Ten isolates (10/30) were from hospitalised patients. 
The proportion of hospitalised patients was 4/21 in 
the period between 2006 and 2012 compared to 6/9 
in 2013. One of the 30 isolates was from blood; the 
rest were eye (2/30), ear (3/30) or respiratory isolates 
(24/30). Among the patients for whom clinical infor-
mation was available (n=23), pneumonia (n=7) and 
acute otitis media (AOM) (n=5) were the most frequent 
infection types. At least seven of the 30 patients were 
predisposed for respiratory tract infections due to 
underlying chronic condition (Table 1).
Strain characterisation
All isolates but one (Hif) lacked polysaccharide capsule 
genes and were categorised as nontypeable (NTHi). The 
isolates were biotypes I (proportion: 3/30), II (4/30), III 
Figure 1
Phylogram of ftsI DNA sequences from Haemophilus influenzae with high-level penicillin-binding protein 3-mediated beta-
lactam resistance (high-rPBP3), Norway, 2006–2013 (n=30)
The phylogram was constructed using unweighted pair group method with arithmetic mean (UPGMA) and based on ftsI DNA sequences 
(transpeptidase domain, nucleotides 1010–1719) including H. influenzae Rd KW20 (GenBank accession number: U32793) as reference and H. 
parainfluenzae (European Molecular Biology Laboratory (EMBL) accession number: AB267856) as outgroup. 
The scale is DNA divergence. 
Labels indicate isolate numbers, ftsI alleles, penicillin-binding protein 3 (PBP3) types (Table 1), multilocus sequence typing sequence types 
(ST) and clonal complexes (CC). 
Colours indicate PBP3 groups. Asterisks indicate ftsI alleles carried by unrelated STs.
Year/county of isolation and assignment to clonal groups (CG) to the right.
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(14/30) and IV (9/30). The Hif isolate and the blood iso-
late were both biotype I.
Twelve STs were represented, including ST1282 and 
ST1287 not previously registered in the MLST database 
(Table 1). Eleven of the 12 STs belonged to nine CCs; 
the last (ST1287) could not be assigned to a CC. ST1197 
(CC395) was the most frequent ST (10/30). Two STs 
(ST1197 and ST836) encompassed both biotype III (ODC 
negative) and IV isolates (ODC positive).
ftsI/PBP3 genotypes
Ten ftsI alleles, encoding seven PBP3 substitution 
types and carried by one to 10 isolates, were observed 
(Table 1). Two ftsI alleles (ftsI-2 and ftsI-4) were present 
in unrelated STs (Figure 1).
The majority of isolates (proportion: 23/30) had the 
N526K first stage substitution and were thus catego-
rised as group III (11/30) or group III+ (12/30). Seven 
isolates (7/30) had the R517H first stage substitution 
and were thus categorised as group III-like (3/30) or 
group III-like+ (4/30).
The third stage substitution L389F was present in 16 of 
30 isolates (Table 1).
Clonal groups
Five clusters comprising two to 10 isolates with iden-
tical MLST-ftsI allelic profiles (clonal groups, CG) were 
identified, accounting for 22 of 30 isolates. Eight 
isolates of 30 had unique MLST-ftsI allelic profiles, 
including the single Hif isolate and the single invasive 
isolate (Table 1).
CG2 (n = 10 isolates) was found in two separate geo-
graphical regions (Oslo region and Western Norway) 
during a period of three years. To confirm genetic 
relationship, PFGE of seven isolates belonging to CG2 
(one beta-lactamase positive and six beta-lactamase 
negative isolates) was performed, and four related 
pulsotypes (1–4) were observed (Figure 2). Pulsotypes 
2 (n = 2), 3 (n = 1) and 4 (n = 1) differed from pulsotype 
1 (n = 3) by two, two and three bands, respectively. 
Pulsotype 1 was observed in both geographical regions. 
No pulsotypes differed by more than five bands.
The three CG4 isolates were sampled during a period of 
four days from one hospitalised patient and two outpa-
tients related to the same hospital. CG5 (n = 4) included 
two patients from the same household (patients 27 
and 28) and was restricted to one hospital department 
within a period of 16 days.
The clonal groups (and the single strains) differed con-
siderably with respect to PBP3 resistance genotypes 
and co-resistance (Table 1). Notably, in contrast to 
CG1 and CG2, the third stage L389F substitution was 
present in CG3, CG4 and CG5. CG1 and CG2 had no co-
resistance to non-beta-lactams, whereas CG4 was mul-
tidrug resistant.
Figure 2
Pulsed-field gel electrophoresis (PFGE) band patterns and pulsotypes for Haemophilus influenzae isolates of clonal group 2, 
Norway, 2006–2013 (n=7) 
Isolate Year County Region Pulsotype
Std
2 2007 Ve O 3
15 2010 SF W 1
13 2009 SF W 2
Std
12 2009 SF W 2
14 2009 SF W 1
8 2008 Ve O 1
4 2007 Os O 4
Std
O: Oslo region; Os: Oslo county; SF: Sogn og Fjordane county; Std: size standard (Staphylococcus aureus NCTC 8325); Ve: Vestfold county;  
W: Western Norway. 
Labels indicate isolate numbers, year, county and region of isolation, and pulsotype.
 The seven isolates depicted are described in Table 1. Isolate 2 is TEM-1 beta-lactamase positive, the remaining isolates are beta-lactamase 
negative. 
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Penicillin-binding protein 3-mediated 
resistance
All strains were categorised as resistant to at least one 
of the extended-spectrum cephalosporins cefotaxime, 
ceftriaxone, cefixime, cefepime and ceftaroline; pro-
portions of resistant isolates varied from 14/30 for cef-
triaxone to 29/30 for the oral agent cefixime (Table 2). In 
general, strains with the N526K first stage substitution 
had higher MICs to extended-spectrum cephalosporins 
(except cefixime) than R517H strains. Furthermore, the 
third stage L389F substitution was generally associ-
ated with higher MICs to extended-spectrum cepha-
losporins and meropenem. Notably, eight of 12 group 
III+ isolates (N526K, S385T and L389F) were non-sus-
ceptible to meropenem (Table 3).
Individual susceptibility profiles and resistance geno-
types are shown in Figure 3. In contrast to other group 
III isolates, the single invasive ST1287 isolate (isolate 
number 18) was categorised as susceptible to ampicil-
lin (MIC = 1 mg/L), cefotaxime (MIC ≤ 0.12 mg/L), cef-
triaxone (MIC ≤ 0.03 mg/L), cefixime (MIC = 0.12 mg/L) 
and cefepime (MIC = 0.25 mg/L). Conversely, the sin-
gle ST124 Hif isolate (isolate number 21) generally 
expressed higher resistance levels to beta-lactams 
than other group III+ isolates.
Figure 3. Year-to-year overview of Haemophilus influ-
enzae isolates with high-level penicillin-binding pro-
tein 3-mediated beta-lactam resistance (high-rPBP3), 
Norway, 2006–2013 (n=30) 
Table 2
Antimicrobial susceptibility of Haemophilus influenzae isolates with high-level penicillin-binding protein 3-mediated beta-
lactam resistance (high-rPBP3), Norway, 2006–2013 (n = 30)
Agents MIC range (mg/L) MIC50 (mg/L) MIC90 (mg/L) Breakpoints (S ≤ /R > )a
R or I/R
n (%)b
Ampicillinc 1 – ≥ 8 4 ≥ 8 1/1 29 (97)
Amoxicillind 4 – 32 8 8 2/2 30 (100)
Cefuroxime 2 – ≥ 16 8 ≥ 16 1/2 1 (3) / 29 (97)
Cefotaxime ≤ 0.12 – ≥ 4 0.25 1 0.12/0.12 26 (87)
Ceftriaxone ≤ 0.03 – 2 0.12 0.5 0.12/0.12 14 (47)
Cefixime 0.12 – ≥ 2 0.5 ≥ 2 0.12/0.12 29 (97)
Cefepime 0.25 – ≥ 4 1 2 0.25/0.25 28 (93)
Ceftaroline 0.03 – 0.25 0.12 0.25 0.03/0.03 26 (87)
Imipenem ≤ 0.5 – 2 1 1 2/2 0 (0)
Meropeneme 0.12 – 2 0.25 0.5 0.25/1e 9 (30) / 1 (3)
Ciprofloxacin ≤ 0.06 – 2 ≤ 0.06 0.25 0.5/0.5 3 (10)
Levofloxacin ≤ 0.03 – 1 ≤ 0.03 0.25 1/1 0 (0)
Chloramphenicol 0.25 – ≥ 8 0.5 ≥ 8 2/2 4 (13)
Rifampicinf 0.25 – 1 0.5 0.5 1/1f 0 (0)
Tetracycline 0.5 – ≥ 8 0.5 ≥ 8 1/2 0 (0) / 4 (13)
Doxycycline 0.25 – 2 0.25 2 1/2 4 (13) / 0 (0)
Minocycline 0.12 – 0.5 0.25 0.5 1/2 0 (0) / 0 (0)
Trimethoprim-sulfamethoxazole 0.12 – ≥ 4 0.5 ≥ 4 0.5/1 0 (0) / 13 (43)
Erythromycing 2 – 4 2 4 0.5/16g 30 (100) / 0 (0)
Clarithromycing 2 – 16 4 8 1/32g 30 (100) / 0 (0)
Azithromycing ≤ 0.25 – 1 0.5 0.5 0.12/4g 30 (100) / 0 (0)
Roxithromycing 2 – 16 4 8 1/16g 30 (100) / 0 (0)
Telithromycing 0.5 – 2 1 1 0.12/8g 30 (100) / 0 (0)
I: intermediate; MIC: minimum inhibitory concentration; R: resistant; S: susceptible.
a  European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints [6]. The I category is inferred from the S and R 
breakpoints.
b  Isolates categorised as R (when only S and R categories exist) or as I/R (when an I category is defined).
c  Beta-lactamase positive isolates (n = 11) tested in the presence of sulbactam (2:1 ratio).
d  Beta-lactamase positive isolates (n = 11) tested in the presence of clavulanic acid (2:1 ratio).
e  Meningitis breakpoints. All isolates were susceptible according to general breakpoints (2/2).
f  Prophylaxis breakpoints.
g  Macrolide breakpoints categorise the wild type population as intermediately susceptible.
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Co-resistance
A total of 11 of 30 strains produced beta-lactamase 
and all were TEM-1 positive (Table 1). Co-resistance to 
trimethoprim-sulfamethoxazole (13/30) was frequent. 
Four of 30 isolates were resistant to chlorampheni-
col and tetracycline, including the three CG4 isolates 
and a single isolate belonging to the same clonal 
complex (CC503) as those forming the CG4. No iso-
lates expressed increased resistance to macrolides or 
rifampicin (Table 3).
Five of 30 isolates had ciprofloxacin MIC > 0.06 mg/L 
and possessed amino acid substitutions in the QRDR of 
GyrA and/or ParC. Three isolates, all belonging to CG4, 
had substitutions in both proteins and were clinically 
resistant to ciprofloxacin. Two isolates, both CG3, had 
only one significant GyrA substitution and quinolone 
MICs within the susceptible category (Table 4).
Case reports
The clinical course was evaluated for three patients 
with well-defined serious infections most likely caused 
by one of the study isolates (patients and isolates 18, 
27 and 28). Isolate 18 was cultured from the blood of 
a patient with X-ray confirmed pneumonia, chronic 
obstructive pulmonary disease (COPD), hypogam-
maglobulinemia, chronic lymphocytic leukaemia and 
myasthenia gravis (Table 1). The strain was catego-
rised as susceptible to cefotaxime (MIC ≤ 0.12 mg/L, 
Figure 3). The patient responded well to initial paren-
teral therapy with cefotaxime (three days) followed by 
ciprofloxacin orally.
Isolates 27 and 28 belonged to CG5 and were beta-lac-
tamase positive and resistant to ampicillin-sulbactam 
(MIC = 8 mg/L) and cefotaxime (MIC = 1 mg/L) accord-
ing to EUCAST breakpoints [6]. Both were isolated 
from sputum in patients with X-ray confirmed pneu-
monia (C-reactive protein ≥ 160 mg/L; norm: <5 mg/L) 
and significant co-morbidity. Patient 27 (cardiovas-
cular disease) responded to therapy with cefotaxime 
(dosage 2 g three times a day) after initial treatment 
with benzylpenicillin. Patient 28 (disseminated cancer) 
responded to ciprofloxacin after initial treatment with 
piperacillin-tazobactam.
Discussion
We have characterised 30 clinical H. influenzae isolates 
from Norway with high-level PBP3-mediated beta-lac-
tam resistance, including 23 isolates possessing both 
the S385T and N526K substitutions. Previously, iso-
lates with this genotype (group III and group III+) have 
primarily been reported from Japan [14] and Korea [15].
The prevalence of low-rPBP3 in respiratory NTHi in 
Norway has increased gradually since 2001 and was 
estimated to 15% in 2007; 113 low-rPBP3 and three 
high-rPBP isolates (isolates 4–6 in this study) were 
reported among 795 surveillance isolates in 2007 [8]. 
When the prevalence of low-rPBP3 in Japan in the 1990s 
reached approximately the same level as in Norway in 
2007, the prevalence of high-rPBP3 isolates increased 
from zero to 29% in few years [14]. Similar observations 
were reported from Korea during the 2000s [15]. NTHi 
was characterised as an emerging pathogen in a most 
Table 3
Penicillin-binding protein 3 (PBP3) groups and susceptibility to cephalosporins and carbapenems of Haemophilus 
influenzae isolates with high-level PBP3-mediated beta-lactam resistance (high-rPBP3), Norway, 2006–2013 (n=30)
Agents
Third stage high-rPBP3a Second stage high-rPBP3b
Group III+ (n=12) Group III-like+ (n=4) Group III (n=11) Group III-like (n=3)
MIC50 
(mg/L)
R or I/R 
n (%)c
MIC50 
(mg/L)
R or I/R 
n (%)c
MIC50 
(mg/L)
R or I/R 
n (%)c
MIC50 
(mg/L)
R or I/R 
n (%)c
Cefuroxime 8 1 (8) / 11 (92) 8 0 (0) / 4 (100) 8
0 (0) / 11 
(100) ≥16
0 (0) / 3 
(100)
Cefotaxime 1 12 (100) 0.5 4 (100) 0.25 9 (82) ≤0.12 1 (33)
Ceftriaxone 0.25 10 (83) 0.25 4 (100) 0.06 0 (0) 0.06 0 (0)
Cefixime 0.5 12 (100) ≥2 4 (100) 0.25 10 (91) ≥2 3 (100)
Cefepime 2 12 (100) 1 4 (100) 0.5 10 (91) 0.5 2 (67)
Ceftaroline 0.25 12 (100) 0.12 4 (100) 0.06 10 (91) 0.03 0 (0)
Imipenem 1 0 (0) ≤0.5 0 (0) 1 0 (0) 1 0 (0)
Meropenem 0.5 7 (58) / 1 (8)d 0.25 0 (0) / 0 (0)d 0.25 2 (18) / 0 (0)d 0.12 0 (0) / 0 (0)d
a  L389F present. Group III+: S385T, L389F and N526K; group III-like+: S385T, L389F and R517H.
b  L389F absent. Group III: S385T and N526K; group III-like: S385T and R517H.
c  According to European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints [6]. The exact breakpoints are 
presented in Table 2. Isolates categorised as I/R (when an I category is defined) or as R (when only S and R categories exist).
d  Meningitis breakpoints (0.25/1) used for categorisation. All isolates were susceptible according to general breakpoints (2/2).
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recent review article [1]. Emphasising the emergence 
and spread of strains with PBP3-mediated resistance, 
the authors recommended implementation of standard-
ised surveillance protocols and typing methodologies.
We recently suggested MLST-ftsI typing as a tool for 
molecular surveillance of PBP3-mediated resistance in 
H. influenzae [8]. By this approach, DNA-based resis-
totyping using the transpeptidase region as an addi-
tional allele is combined with MLST allelic profiles. 
This sequence is readily available if PBP3 resistance 
genotyping is done by sequencing. In that study [8], 
MLST clonal complexes corresponded well to PFGE 
clusters. Addition of the ftsI allele to MLST allelic pro-
files increased the discriminatory power compared with 
MLST alone and MLST combined with PBP3 substitu-
tion patterns, without compromising consistency with 
PFGE-based grouping. The observation that CG2 in the 
present study (and most MLST-ftsI types in the previ-
ous study) encompassed related pulsotypes supports 
the validity of the typing scheme although discrimina-
tory power is inferior to PFGE. Increasing the length 
of the ftsI fragment could improve resolution but this 
would most likely be at the cost of reduced sensitivity 
for clone detection.
So far, the molecular epidemiology of high-rPBP3 
strains is poorly described. However, two invasive 
group III-like isolates recently reported from Spain had 
MLST allelic profiles (ST155 and ST1118) identical or 
closely related to CG1 in the present study; the Spanish 
isolates and CG1 also had identical PBP3 substitution 
patterns as far as comparison is possible [3]. These 
observations suggest that CG1 and the two Spanish 
isolates may be representatives of a virulent high-
rPBP3 NTHi clone distributed within Europe.
Figure 3
Year-to-year overview of Haemophilus influenzae isolates with high-level penicillin-binding protein 3-mediated beta-lactam 
resistance (high-rPBP3), Norway, 2006–2013 (n=30)
MIC: minimum inhibitory concentration; PBP3: penicillin-binding protein 3.
Colours indicate the following parameters: A, CGs (identical MLST-ftsI profiles, Table 1); B, PBP3 resistance genotypes (grouped according 
to substitutions in positions 385, 389, 517 and 526, Table 1); C, co-resistance to non-beta-lactam antimicrobial agents (number of classes, 
including low-level resistance to quinolones) and beta-lactamase (β); D-I, MICs (broth microdilution) to extended-spectrum cephalosporins 
and meropenem. 
Green numbers on the MIC scale indicate values below the European Committee on Antimicrobial Susceptibility Testing (EUCAST) 
S-breakpoint [6]. Each box indicates the same isolate in all diagrams. Isolates collected the same year (columns) are sorted by PBP3 groups, 
clonal groups and cefotaxime MIC.
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Travel history suggested that one isolate in this study 
may have been imported from Thailand, although an 
isolate with identical MLST-ftsI profile was observed in 
Norway two years earlier (CG3).
In this study, CG4 and CG5 were respectively restricted 
to one hospital (both hospitals located in Western 
Norway) and sampled within short time periods. Two 
of the CG5 isolates were sampled from persons within 
the same household. Person-to-person transmission 
of nontypeable H. influenzae has been reported previ-
ously, including an outbreak with an amoxicillin-resist-
ant strain in a respiratory ward [27] and intrafamilial 
transmission of rPBP3 strains [28]. These observations 
highlight the importance of hygiene measures in health 
institutions to prevent nosocomial spread.
The observation of identically mutated ftsI alleles in 
unrelated STs suggests horizontal gene transfer (HGT). 
Similar observations have been reported by us previ-
ously [8]. Thus, resistant strains may have developed 
in Norway by HGT of alleles conferring resistance; 
these alleles may have been imported at an earlier 
stage or have evolved locally. The observation of allele 
mosaicism in H. influenzae [29] supports this interpre-
tation and strongly suggests that allele transfer has 
occurred via transformation and recombination with 
the chromosome.
By EUCAST clinical breakpoints [6], all isolates were 
categorised as resistant to at least one extended-
spectrum cephalosporin. Clinically relevant differ-
ences in resistance profiles between PBP3 groups 
were observed. Isolates possessing the third stage 
substitution L389F were generally more resistant to 
cephalosporins than the remaining isolates, consistent 
with the results of a previous investigation using site-
directed mutagenesis and transformation to study the 
impact of PBP3 substitutions on beta-lactam suscep-
tibility [13]. Notably, most L389F positive isolates in 
the present study were ceftriaxone resistant, while all 
isolates lacking this substitution were ceftriaxone sus-
ceptible. The three-stage classification system used in 
this study, separating between isolates with and with-
out the L389F substitution, appears to reflect the step-
wise development of PBP3-mediated resistance better 
than systems based on S385T and R517H/N526K only.
We evaluated the effectiveness of the antimicrobial 
therapy for three patients with X-ray confirmed pneu-
monia associated with study strains. Notably, one 
patient responded to therapy with high dosage of cefo-
taxime although the isolate (from sputum) was catego-
rised as resistant (MIC = 1 mg/L) according to EUCAST 
clinical breakpoints [6]. This is consistent with current 
EUCAST non-species related breakpoints for cefotax-
ime based on a dose of at least 2 g three times a day 
(R > 2 mg/L) [6]. The isolate would have been catego-
rised as susceptible to cefotaxime by CLSI breakpoints 
for H. influenzae (S ≤ 2 μg/mL) [7].
The single ST1287 blood isolate from an immunocom-
promised patient with pneumonia is to our knowledge 
the first reported invasive group III high-rPBP3 isolate 
from Europe. This strain generally expressed lower 
MICs to beta-lactams than noninvasive group III study 
isolates and was categorised as cefotaxime suscep-
tible (MIC ≤ 0.12 mg/L). The patient responded well to 
cefotaxime therapy.
Conversely, the single Hif group III+ isolate was more 
resistant than nontypeable isolates with compa-
rable genotypes. These observations suggest that 
Table 4
GyrA/ParC amino acid substitutions in Haemophilus influenzae isolates with high-level penicillin-binding protein 
3-mediated beta-lactam resistance (high-rPBP3) and raised minimum inhibitory concentrations to quinolones, Norway, 
2006–2013 (n = 5)a
Isolateb
MICs (mg/L) and breakpoints 
(S ≤ /R > )c GyrA
d ParCd
CIP (0.5/0.5) LEV (1/1) S84 D88 S84 N138 G206
16 0.25 0.25 L – – – R
23 0.25 0.25 L – – – R
24 2 1 L N I S –
25 2 1 L N I S –
26 2 1 L N I S –
CIP: ciprofloxacin; LEV: levofloxacin; MIC: minimum inhibitory concentration;  –: no substitution.
a  The remaining 25 isolates had ciprofloxacin MICs ≤ 0.06 mg/L and levofloxacin MICs ≤ 0.03 mg/L.
b  Further characteristics are described in Table 1.
c  European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints [6]. 
d  Amino acid substitutions in GyrA (64–177) and ParC (66–236).
11www.eurosurveillance.org
strain-associated mechanisms other than PBP3 sub-
stitutions may modify resistance levels in rPBP3 iso-
lates. Increased efflux due to mutations in the acrR 
gene, encoding a repressor of the AcrAB efflux pump, 
is associated with high-level macrolide resistance in H. 
influenzae and may increase resistance to ampicillin in 
rPBP3 strains [30]. The acrR gene was not sequenced in 
the present study but all isolates expressed wild-type 
MICs to macrolides.
Co-resistance was more frequent than expected. The 
proportions of trimethoprim-sulfamethoxazole resist-
ant and beta-lactamase positive isolates were twice 
and three times, respectively, the overall reported 
prevalences in respiratory H. influenzae isolates (n = 
677) in a Norwegian nationwide surveillance study in 
2011 [31]. Similarly, resistance rates for ciprofloxacin, 
tetracycline and chloramphenicol in this study were 
10% (3/30), 13% (4/30) and 13% (4/30), respectively, 
compared with 0.1%, 0.4% and 0.7% in the 2011 sur-
veillance report.
EUCAST define resistance to ciprofloxacin as an excep-
tional phenotype in H. influenzae and recommend that 
such isolates are referred to a reference laboratory 
[5,6]. Quinolone resistance in this species is usually 
due to QRDR substitutions in subunit A of topoisomer-
ase II (GyrA) and subunit A of topoisomerase IV (ParC). 
Resistance levels depend largely on the number of 
substitutions in the positions 84 and 88 in both pro-
teins [32]. Isolates with single substitutions are usu-
ally low-level resistant but other mechanisms such as 
the transferable plasmid-mediated acetyl transferase 
gene aac(6’)-lb-cr may increase resistance [33,34]. 
The QRDR substitution patterns and quinolone MICs 
observed in this study are consistent with previous 
reports [26,32]. The nalidixic acid 30 μg disk is supe-
rior to the ciprofloxacin 5 μg disk for detection of iso-
lates with low-level quinolone resistance and may be 
used for screening [6,26].
Quinolone resistance in H. influenzae is associated 
with hypermutability [33]. It seems likely that hyper-
mutability also increases the ability to acquire PBP3 
substitutions by spontaneous mutations, favouring the 
development of strains with both resistance mecha-
nisms. To our knowledge, CG4 represent the first cipro-
floxacin-resistant high-rPBP3 isolates reported outside 
Japan, and the first clonal cluster ever with this particu-
lar combination of resistance mechanisms.
The CG4 isolates had TEM-1 beta-lactamase and were 
resistant to chloramphenicol, tetracycline and tri-
methoprim-sulfamethoxazole. This resistance profile 
suggests the presence of a conjugative large plasmid 
[35], now recognised as an integrating and conjugative 
element (ICE) designated ICEHin1056 [36]. The resisto-
type of CG4 might thus be the result of two independ-
ent factors: hypermutability, leading to PBP3 and 
QRDR substitutions, and the acquisition of ICEHin1056. 
Hypermutable H. influenzae are prevalent in cystic 
fibrosis (CF) patients [37]. One CG4 isolate was found 
in sputum from a CF patient; another isolate was from 
nasopharynx of a patient with primary ciliary dyski-
nesia (PCD). High antibiotic pressure in these patient 
categories may contribute to selection of multidrug 
resistant strains.
The ST of CG4 (ST159) is associated with increased viru-
lence in chronic obstructive pulmonary disease due to 
an additional IgA1 protease, encoded by the igaB gene 
[38].
The emergence of clonally related high-rPBP3 isolates 
in Norway is a cause for concern. As previously reported 
from Japan and Korea, a shift from low-level to high-
level rPBP3 might alter the epidemiological situation 
dramatically in few years [14,15]. A similar development 
in Europe would threaten current recommendations for 
empiric antimicrobial treatment in severe disease [1]. 
The situation urges for improved surveillance systems 
for antimicrobial resistance in H. influenzae in Europe.
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